HUP0203444A2 - (S)-2-Etoxi-3-[4-{2-[4-(metánszulfonil-oxi)-fenil]-etoxi}-fenil]-propionsav kristályos formája, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása - Google Patents

(S)-2-Etoxi-3-[4-{2-[4-(metánszulfonil-oxi)-fenil]-etoxi}-fenil]-propionsav kristályos formája, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása

Info

Publication number
HUP0203444A2
HUP0203444A2 HU0203444A HUP0203444A HUP0203444A2 HU P0203444 A2 HUP0203444 A2 HU P0203444A2 HU 0203444 A HU0203444 A HU 0203444A HU P0203444 A HUP0203444 A HU P0203444A HU P0203444 A2 HUP0203444 A2 HU P0203444A2
Authority
HU
Hungary
Prior art keywords
ethoxy
crystalline form
phenyl
preparation
solvate
Prior art date
Application number
HU0203444A
Other languages
English (en)
Inventor
Maria Boije
Karol Horvath
Tord Inghardt
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9904416A external-priority patent/SE9904416D0/xx
Priority claimed from SE0001187A external-priority patent/SE0001187D0/xx
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0203444A2 publication Critical patent/HUP0203444A2/hu
Publication of HUP0203444A3 publication Critical patent/HUP0203444A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgya az képletű (S)-2-etoxi-3-[4-{2-[4-(metánszulfonil-oxi)-fenil]-etoxi}-fenil]- propionsav új, kristályos formája vagygyógyszerészetileg elfogadható sója vagy szolvátja. A találmány tárgyatovábbá egy eljárás anyagcsere-zavarokkal összefüggő egy vagy többállapot kezelésére, különösen az inzulinrezisztencia szindrómávalkapcsolatban, és a vegyület kristályos formájának gyógyszerészetilegelfogadható sójának vagy szolvátjának alkalmazása a már említett egyvagy több állapot kezelésére szolgáló gyógyszer előállítására. Atalálmány további tárgya olyan gyógyszerkészítmény, amely a vegyületkristályos formáját vagy gyógyszerészetileg elfogadható sóját vagyszolvátját tartalmazza hatóanyagként, és a talállmány tárgya avegyület kristályos formájának vagy gyógyszerészetileg elfogadhatósójának vagy szolvátjának előállítására szolgáló eljárás is. Ó
HU0203444A 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof HUP0203444A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904416A SE9904416D0 (sv) 1999-12-03 1999-12-03 Crystalline form
SE0001187A SE0001187D0 (sv) 2000-04-03 2000-04-03 Crystalline form
PCT/SE2000/002384 WO2001040171A1 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid

Publications (2)

Publication Number Publication Date
HUP0203444A2 true HUP0203444A2 (hu) 2003-02-28
HUP0203444A3 HUP0203444A3 (en) 2003-05-28

Family

ID=26655058

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203444A HUP0203444A3 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof

Country Status (30)

Country Link
US (1) US6531622B1 (hu)
EP (1) EP1237855B1 (hu)
JP (1) JP2003515582A (hu)
KR (1) KR20030029040A (hu)
CN (1) CN1198799C (hu)
AR (1) AR029412A1 (hu)
AT (1) ATE261431T1 (hu)
AU (1) AU773777B2 (hu)
BR (1) BR0016131A (hu)
CA (1) CA2392038A1 (hu)
CO (1) CO5271735A1 (hu)
CZ (1) CZ20021902A3 (hu)
DE (1) DE60008921T2 (hu)
DK (1) DK1237855T3 (hu)
EE (1) EE200200278A (hu)
ES (1) ES2215769T3 (hu)
HK (1) HK1048980A1 (hu)
HU (1) HUP0203444A3 (hu)
IL (1) IL149577A0 (hu)
IS (1) IS6400A (hu)
MX (1) MXPA02005327A (hu)
MY (1) MY135954A (hu)
NO (1) NO20022598D0 (hu)
NZ (1) NZ518925A (hu)
PL (1) PL357118A1 (hu)
PT (1) PT1237855E (hu)
RU (1) RU2268880C2 (hu)
SK (1) SK7652002A3 (hu)
TR (1) TR200401333T4 (hu)
WO (1) WO2001040171A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9812772A (pt) 1997-10-27 2000-10-10 Reddy Research Foundation "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos"
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
NZ510904A (en) 1998-10-29 2003-08-29 Dr An process for the preparation of antidiabetic agents
US7084177B2 (en) * 1999-12-03 2006-08-01 Astrazeneca Ab Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102004035034A1 (de) * 2004-07-20 2006-02-16 Degussa Ag Racematspaltung von p-Hydroxyphenyl-2-alkoxy-propionsäuren
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I

Also Published As

Publication number Publication date
DK1237855T3 (da) 2004-06-14
EE200200278A (et) 2003-06-16
HUP0203444A3 (en) 2003-05-28
PL357118A1 (en) 2004-07-12
MXPA02005327A (es) 2002-12-06
WO2001040171A1 (en) 2001-06-07
MY135954A (en) 2008-07-31
CN1198799C (zh) 2005-04-27
RU2268880C2 (ru) 2006-01-27
IL149577A0 (en) 2002-11-10
EP1237855B1 (en) 2004-03-10
BR0016131A (pt) 2002-08-20
AU2035001A (en) 2001-06-12
NO20022598L (no) 2002-05-31
NZ518925A (en) 2004-06-25
EP1237855A1 (en) 2002-09-11
IS6400A (is) 2002-05-28
CZ20021902A3 (cs) 2002-11-13
SK7652002A3 (en) 2002-11-06
ES2215769T3 (es) 2004-10-16
JP2003515582A (ja) 2003-05-07
HK1048980A1 (en) 2003-04-25
CO5271735A1 (es) 2003-04-30
CN1409701A (zh) 2003-04-09
US6531622B1 (en) 2003-03-11
NO20022598D0 (no) 2002-05-31
RU2002113450A (ru) 2004-01-10
AR029412A1 (es) 2003-06-25
DE60008921D1 (en) 2004-04-15
CA2392038A1 (en) 2001-06-07
KR20030029040A (ko) 2003-04-11
ATE261431T1 (de) 2004-03-15
DE60008921T2 (de) 2005-01-20
AU773777B2 (en) 2004-06-03
TR200401333T4 (tr) 2004-08-23
PT1237855E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
HUP0203444A2 (hu) (S)-2-Etoxi-3-[4-{2-[4-(metánszulfonil-oxi)-fenil]-etoxi}-fenil]-propionsav kristályos formája, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása
SE9904413D0 (sv) Comminuted form
JP2002513793A5 (hu)
IL139636A (en) (s)-2-ethoxy-3-[4-(2{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof in the manufacture of medicament for the prophylaxis or treatment of clinical conditions associated with insulin resistance
NZ600129A (en) Capsule formation of pirfenidone and pharmaceutically acceptable excipients
JP2008512408A5 (hu)
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
EA200602016A1 (ru) ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ
ATE302774T1 (de) Arzneimittel enthaltend betamimetika und ein neues anticholinergikum
HRP20130092T4 (hr) Karbamoil-cikloheksani za lijeäśenje akutne manije
HRP20151138T1 (hr) Dihidroetorfini i njihovo pripremanje
RU2005129999A (ru) Диарилциклоалкильные производные, способы их получения и их применение в качестве лекарственного средства
EP4279138A3 (en) Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof
HRP20120344T1 (hr) N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije
JP2014504648A5 (hu)
HUP0303584A2 (hu) Egy hidroximsav-halogenid-származék alkalmazása neurodegeneratív betegségek kezelésére
CA2499721A1 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
HUP0202679A2 (hu) 2-(4-Hidroxi-fenil)-1-[4-(2-amin-1-il-etoxi)-benzil]-1H-indol-5-olok glükopiranozid konjugátumai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402515A2 (hu) Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
JP2008115167A (ja) トラネキサム酸を含有する気道杯細胞過形成抑制剤
SE9904412D0 (sv) Comminuted form
JP2007509946A5 (hu)
RU2009104060A (ru) Новые оптически активные соединения фенилэтаноламинов и способ их получнеия
AR026704A1 (es) Forma cristalina

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished